Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus

Transplant International

Volumn 18, Issue 9, 2005, Pages 1028-1035

  Campistol, Josep M ^a   Holt, David W ^b   Epstein, Solomon ^c   Gioud Paquet, Martine ^d   Rutault, Karine ^d   Burke, James T ^d  

^a HOSPITAL CLÍNIC   (Spain)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c ALBERT EINSTEIN MEDICAL CENTER   (United States)

^d Clinical Research and Development   (France)

Author keywords

Bone metabolism; Cyclosporine; N telopeptides; Serum osteocalcin; Sirolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSTEOCALCIN; RAPAMYCIN; TACROLIMUS; TELOPEPTIDE; CALCIUM; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FRACTURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION; BLOOD; BONE; DRUG EFFECT; GLOMERULUS FILTRATION RATE; METABOLISM; MIDDLE AGED;

ADULT; AGED; BONE AND BONES; CALCIUM; COLLAGEN; COLLAGEN TYPE I; CYCLOSPORINE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OSTEOCALCIN; PEPTIDES; SIROLIMUS;

EID: 26944454882     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00163.x     Document Type: Article

References (37)

1. Epstein S, Shane E, Bilezikian JP. Organ transplantation and osteoporosis. Curr Opin Rheumatol 1995; 7: 255.
2. Shane E, Epstein S. Transplantation osteoporosis. Transplant Rev 2001; 15: 11.
3. Epstein S, Shane E. Transplantation osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis, Vol. 2, 2nd edn. New York, USA: Academic Press, 2001: 327-335.
4. Grotz WH, Mundinger FA, Gugel B, Exner VM, Kirste G, Shollmeyer PJ. Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation 1995; 59: 982.
5. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325: 544.
6. Torregrosa JV, Campistol JM, Montesinos M, et al. Factors involved in the loss of bone mineral density after renal transplantation. Transplant Proc 1995; 27: 2224.
7. Cayco AV, Wysolmerski J, Simpson C, et al. Post-transplant bone disease: evidence for a high bone resorption state. Transplantation 2000; 70: 1722.
8. Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 1996; 28: 105.
9. Sprague SM. Mechanism of transplantation-associated bone loss. Pediatr Nephrol 2000; 14: 650.
10. Babarykin D, Adamsone I, Amerika D, Folkmane I, Rozental R. Disorders of calcium metabolism at various times after renal transplantation. Ann Transplant 1999; 4: 46.
11. Ponticelli C, Aroldi A. Osteoporosis after organ transplantation. Lancet 2001; 357: 1623.
12. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest 1998; 102: 274.
13. Buchinsky FJ, Ma Y, Mann GN, et al. T lymphocytes play a critical role in the development of cyclosporin A-induced osteopenia. Endocrinology 1996; 137: 2278.
14. Cvetkovic M, Mann GN, Romero DF, et al. The deleterious effects of long-term cyclosporine, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994; 57: 1231.
15. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123: 2571.
16. Schlosberg M, Movsowitz C, Epstein S, Ismail F, Fallon MD, Thomas S. The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 1989; 124: 2179.
17. Grasziani G, Aroldi A, Castelnovo C, Bondatti F, DeVecchi A, Ponticelli C. Ciclosporin and calcium metabolism in renal transplanted patients. Nephron 1991; 57: 479.
18. Ugur A, Guvener N, Isiklar I, Turan M, Erdal R, Haberal M. Osteoporosis after renal transplantation: single center experience. Transplantation 2001; 71: 645.
19. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999; 67: 1036.
20. Johnson RWG, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777.
21. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040.
22. Kahan BD, for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194.
23. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of evidence. Kidney Int 2001; 59: 3.
24. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660.
25. Romero DF, Buchinsky FJ, Rucinski B, et al. Rapamycin: a bone sparing immunosuppressant? J Bone Miner Res 1995; 10: 760.
26. Goodman GR, Dissanayake IR, Sodam BR, et al. Immunosuppressant use without bone loss - implications for bone loss after transplantation. J Bone Miner Res 2001; 16: 72.
27. Hofbauer LC, Shui C, Riggs BW, et al. Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001; 280: 334.
28. Gertz BJ, Shao P, Hanson DA, et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 1994; 9: 135.
29. Rosen HN, Dresner-Pollack R, Moses AC, et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 1994; 54: 26.
30. Christenson RH. Biochemical markers of bone metabolism: an overview. Clin Biochem 1997; 30: 573.
31. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
32. Holt DW, Lee T, Johnston A. Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection. Clin Ther 2000; 22(Suppl. B): B38.
33. Nankivell BJ, Gruenwald SM, Allen RDM, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
34. Bryer HP, Isserow JA, Armstrong EC, et al. Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat. J Bone Miner Res 1995; 10: 132.
35. Dissanayake IR, Goodman GR, Bowman AR, et al. Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat. Transplantation 1998; 65: 275.
36. McAlister VC, Gao ZH, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355: 376.
37. Ambuhl PM, Meier D, Wolf B, Dydak U, Boesiger P, Binswanger U. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999; 34: 875.